Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans
By W. Dejnirattisai, A. Jumnainsong, N. Onsirisakul, Patricia Fitton, Sirijitt Vasanawathana, W. Limpitikul, C. Puttikhunt, Carolyn J. Edwards, Thaneeya Duangchinda, Sunpetchuda Supasa and 4 more. Science, 2010
906 citations recorded by the source corpus.
Subfields: Infectious Diseases, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/b557bf1d316d5a724f8c8ad3dad3af9e347c2bfb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Public Health, Environmental and Occupational Health
Citations in the corpus
- From Vaccines to Memory and Back (2010, positive): “The human antibody response to dengue virus has been dissected through the analysis of monoclonal antibodies revealing basic mechanisms of neutralization and infection enhancement (Beltramello et al., 2010; Dejnirattisai et al., 2010).”
- Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms (2011, background): “However, incomplete cleavage appears to be a common occurrence for dengue virus, at least in vitro , yielding immature and partially mature particles that can be bound by pre-M protein-specific antibodie”
- Antibody-dependent enhancement of severe dengue disease in humans (2017, background): “During infection, human DENV virions are thought to be mostly mature (DENV grown in human B cells are mostly mature (72)), and thus the extent to which prM antibodies are relevant to ADE in human infections remains an unanswered question.”
- Dengue: a continuing global threat (2010, background): “The available data suggest that neutralizing antibodies are the major contributors to protective immunity 124,125 , however the role of the cellular immune response requires further study 123 .”
- Modified mRNA vaccines protect against Zika virus infection (2017, neutral): “The highly conserved FL epitope in DII of the flavivirus E protein is immunodominant in humans (Beltramello et al., 2010; Crill et al., 2007; Dejnirattisai et al., 2010; Oliphant et al., 2007; Sapparapu et al., 2016; Stettler et al., 2016).”